cAMPfield Therapeutics has launched with a $180 million Series A financing to advance prifemilast, a once-daily oral PDE4B-selective inhibitor, into global trials for moderate-to-severe ulcerative colitis and Crohn’s disease. The San Diego biotechnology company holds development and commercialisation rights outside Greater China through a licence from Newsoara Biopharma and plans a Phase 2b ulcerative colitis study alongside a Phase 2 Crohn’s disease trial.
Why a $180 million Series A gives cAMPfield unusual freedom to test prifemilast properly
The financing is large enough to distinguish cAMPfield Therapeutics from the many asset-centred biotechnology companies launched with capital intended only to reach an initial clinical readout. Frazier Life Sciences led the round, with Deep Track Capital, Forbion, Abingworth, Venrock, Longitude Capital, Novo Holdings and RA Capital participating.
That syndicate provides more than cash. The investors bring experience in inflammatory disease, company formation, clinical development and transactions, potentially giving cAMPfield access to additional capital or strategic options if prifemilast produces convincing mid-stage data.
The size of the round should allow the biotechnology firm to run separate global studies in ulcerative colitis and Crohn’s disease rather than choosing one indication and postponing the other. It should also support manufacturing, regulatory preparation, biomarker analysis and follow-up periods long enough to evaluate whether early disease control can be maintained.
This matters because inflammatory bowel disease programmes can generate misleading results when trials are too small, too short or concentrated in unusually treatment-responsive patients. Induction responses may appear promising while maintenance efficacy, endoscopic improvement or steroid-free remission remains uncertain.
A well-financed company can design trials around clinically demanding outcomes instead of optimising only for speed. However, the financing also raises expectations. Investors have effectively funded a broad development thesis around a single lead medicine, meaning weak Phase 2 results could affect the entire company rather than one programme within a diversified pipeline.
What prifemilast is designed to change about the long-standing PDE4 tolerability problem
Prifemilast, previously known as HPP737 or HY1999, inhibits phosphodiesterase 4, an enzyme that breaks down cyclic adenosine monophosphate inside cells. Increasing cyclic adenosine monophosphate can reduce pro-inflammatory signalling, increase anti-inflammatory activity and influence pathways associated with fibrosis.
The biological rationale is established across several immune-mediated diseases. PDE4 inhibitors have reached the market in conditions including plaque psoriasis, psoriatic arthritis, Behcet’s disease and chronic obstructive pulmonary disease.
The class has nevertheless been restricted by tolerability. Earlier oral PDE4 inhibitors can cause nausea, diarrhoea, vomiting, headache, appetite changes and weight loss. These effects may be manageable for some patients, but they can limit dosing, persistence and the amount of target inhibition that developers can achieve.
cAMPfield’s central claim is that prifemilast is more selective for PDE4B, the subtype associated with much of the desired anti-inflammatory activity, than for PDE4D, which has been linked to dose-limiting adverse effects. If that distinction holds in inflammatory bowel disease, the company may be able to deliver stronger pathway inhibition without recreating the gastrointestinal tolerability burden associated with less selective medicines.
Prifemilast has already been administered to more than 700 clinical trial participants, including more than 250 people with approximately one year of exposure. Earlier development reportedly produced discontinuation rates comparable to placebo and avoided the severe gastrointestinal pattern that has constrained parts of the PDE4 class.
That history reduces some uncertainty about short-term tolerability, but it does not establish safety in inflammatory bowel disease. Patients with active ulcerative colitis or Crohn’s disease already experience diarrhoea, abdominal pain, reduced appetite and weight loss. Even moderate gastrointestinal adverse effects could be more disruptive in this population than in a psoriasis trial.
The relevant question is therefore not whether prifemilast looks cleaner than older PDE4 inhibitors in healthy volunteers or dermatology studies. It is whether patients with active intestinal disease can remain on an effective dose long enough to achieve and maintain remission.
Why psoriasis success supports development without proving efficacy in ulcerative colitis or Crohn’s disease
Newsoara has completed a Phase 3 study of prifemilast in plaque psoriasis in China and is conducting another late-stage study intended to support a possible regulatory application. cAMPfield is using this clinical history to support the candidate’s efficacy and tolerability credentials.
Psoriasis and inflammatory bowel disease share several inflammatory pathways, including signalling involving tumour necrosis factor, interleukin-23 and other immune mediators. Medicines developed for one condition can sometimes succeed in the other, as demonstrated by several biologic and oral therapies used across immune-mediated diseases.
However, shared pathways do not guarantee shared clinical performance. The skin and gastrointestinal tract differ in immune environment, drug exposure requirements, tissue structure and the consequences of incomplete disease control.
A medicine can produce visible improvement in psoriasis plaques without achieving the deeper objectives expected in inflammatory bowel disease, including endoscopic healing, histological improvement, sustained steroid-free remission and prevention of structural complications.
Crohn’s disease creates an additional challenge because inflammation can affect different parts and layers of the gastrointestinal tract. Symptoms may improve without complete control of intestinal damage, while strictures, fistulas and penetrating disease can complicate interpretation.
The psoriasis programme therefore serves mainly as evidence that prifemilast is pharmacologically active and can be taken over meaningful periods. The upcoming trials must establish whether that activity is sufficient for moderate-to-severe intestinal inflammation.
What previous ulcerative colitis data reveal about the promise and weakness of PDE4 inhibition
PDE4 inhibition has already been tested in ulcerative colitis through a Phase 2 study of apremilast. The trial produced encouraging numerical differences in remission, mucosal healing and biomarker outcomes at one dose, suggesting that the mechanism can influence intestinal inflammation.
The study did not meet its primary endpoint, and the higher dose did not consistently outperform the lower dose. That result prevented the programme from establishing a clear development path and showed that pathway validation in another inflammatory disease was not enough to guarantee success in ulcerative colitis.
For cAMPfield, the apremilast experience is both supportive and cautionary. It suggests that PDE4 inhibition can produce a clinical signal in the colon, but it also demonstrates that dose, subtype selectivity, tolerability and trial design can determine whether the signal becomes a viable medicine.
Prifemilast could improve on that profile if PDE4B selectivity allows stronger or more sustained inhibition. Once-daily dosing may also be more convenient than twice-daily treatment, particularly for patients managing several medicines.
The risk is that subtype selectivity improves tolerability without generating a sufficiently large efficacy gain. An oral therapy can be easier to take and still fail commercially if remission rates remain below those achieved with modern targeted medicines.
The Phase 2b ulcerative colitis trial will need to show more than statistical separation from placebo. It should produce a response large enough to remain relevant in a treatment landscape that now includes biologics, Janus kinase inhibitors, sphingosine-1-phosphate receptor modulators and interleukin-23 therapies.
How crowded oral treatment options raise the efficacy threshold for prifemilast
Inflammatory bowel disease treatment has moved beyond a simple choice between conventional immunosuppressants and injectable biologics. Patients with moderate-to-severe disease can now receive oral targeted therapies capable of producing relatively rapid symptom control and clinically meaningful remission.
Janus kinase inhibitors have demonstrated strong efficacy, including in patients previously exposed to advanced therapies. Their use can be limited by boxed warnings, laboratory monitoring and concerns involving serious infection, malignancy, thrombosis and cardiovascular events in selected populations.
Sphingosine-1-phosphate receptor modulators offer another oral approach. They avoid some risks associated with Janus kinase inhibition but carry their own requirements involving cardiac assessment, liver monitoring, infection risk and other precautions.
Prifemilast could occupy a valuable position if it delivers moderate-to-strong efficacy with a less complicated safety profile. A once-daily oral drug that does not require intensive laboratory surveillance could appeal to patients and physicians seeking a treatment before moving to injectable biologics or medicines with broader systemic warnings.
Convenience alone will not be sufficient. Biologics increasingly offer infrequent dosing, subcutaneous self-administration and well-established long-term evidence. Some patients may prefer an injection every several weeks over a tablet taken every day, especially when the biologic has a stronger probability of deep remission.
The commercial opportunity therefore depends on the balance among efficacy, safety, speed of response and durability. cAMPfield must avoid positioning prifemilast merely as an easier option. It needs to show that the medicine can control disease strongly enough to change treatment sequencing.
Why separate ulcerative colitis and Crohn’s disease trials create opportunity and execution risk
cAMPfield plans a global Phase 2b trial in moderate-to-severe ulcerative colitis and a Phase 2 trial in Crohn’s disease. Developing both indications can expand the eventual commercial opportunity and establish whether PDE4B inhibition has broad relevance across inflammatory bowel disease.
Ulcerative colitis may offer the more straightforward early test because disease activity can be assessed through symptoms, endoscopy and biomarkers in a relatively defined part of the gastrointestinal tract. A successful study could provide a clear proof of concept for prifemilast.
Crohn’s disease is more heterogeneous. Disease location, previous surgery, penetrating complications and differences in inflammatory burden can make trials harder to interpret. Endoscopic response may require longer treatment, and symptoms do not always correlate closely with objective inflammation.
Running both studies should help the company identify where the candidate performs best. It also creates operational pressure. The biotechnology firm must recruit across countries, manage different endoscopic scoring systems, ensure central reading quality and maintain adequate drug supply for parallel programmes.
Trial design will determine whether the results answer commercially relevant questions. Studies dominated by patients who have never received advanced therapy may produce stronger efficacy but provide less information about the difficult population increasingly seen in specialist practice.
Including heavily pretreated patients creates a tougher test but could establish differentiation if prifemilast works after biologic or oral targeted therapy failure. cAMPfield may need stratified analyses to determine whether prior treatment exposure changes response.
Can tolerability become a true commercial advantage rather than a development slogan?
Drug developers frequently describe new oral immune therapies as safer or better tolerated before adequate comparative evidence exists. Prifemilast has an encouraging exposure history, but the inflammatory bowel disease studies will need to measure tolerability with unusual care.
Discontinuation rates will be important because they capture whether adverse effects are severe enough to prevent continued use. Detailed reporting of nausea, diarrhoea, vomiting, headache and weight change will be particularly relevant.
Investigators must also distinguish drug-related gastrointestinal effects from symptoms caused by active disease. If both improve or worsen simultaneously, conventional adverse-event reporting may not fully explain the patient experience.
Longer-term evidence will be required for infections, malignancies, psychiatric effects, pregnancy considerations and cardiovascular outcomes. A small mid-stage trial cannot exclude rare risks, even when the mechanism appears more selective.
The strongest commercial profile would combine low discontinuation rates with limited monitoring requirements and sustained objective disease control. That combination could allow prifemilast to compete as an earlier advanced therapy, particularly for patients reluctant to begin injections or therapies associated with more complex warnings.
A weaker outcome would involve good tolerability but only modest remission. In that scenario, clinicians may reserve the medicine for milder disease or patients unable to use stronger options, limiting the value implied by the company’s financing.
What the Newsoara licence says about cross-border biotechnology asset creation
cAMPfield’s formation reflects a continuing shift in biotechnology development, with investors building new United States companies around clinical assets sourced from China or other international markets.
Newsoara obtained prifemilast from vTv Therapeutics and generated further development experience in China. cAMPfield now holds rights outside Greater China and will attempt to translate that package into global inflammatory bowel disease programmes.
This structure allows investors to start with an asset that has already passed through early human testing rather than financing discovery and initial safety work. It can reduce time to value-creating clinical data and lower some scientific risk.
Cross-border licensing introduces other challenges. Manufacturing processes, datasets, regulatory documentation and clinical standards must be transferred across organisations. Global regulators may scrutinise how overseas evidence was generated and whether it applies to the populations included in new trials.
cAMPfield must also coordinate its strategy with Newsoara’s retained Greater China rights. Divergent trial designs or development priorities could create complexity, although complementary datasets may strengthen the overall programme if managed consistently.
The licence demonstrates that substantial venture capital remains available for clinical assets with extensive prior exposure and a plausible differentiation thesis. It does not mean that investors regard the drug as clinically de-risked.
What industry observers will watch as prifemilast enters global IBD trials
The first critical detail will be the ulcerative colitis trial design. Endpoint definitions, treatment duration, prior therapy exposure and placebo assumptions will determine how convincingly the study can establish proof of concept.
Industry observers will also examine dose selection. The entire PDE4B thesis depends on reaching sufficient anti-inflammatory exposure without triggering the adverse effects that have constrained the class.
Endoscopic and histological outcomes will matter more than symptom improvement alone. Regulators and gastroenterologists increasingly expect objective evidence that a therapy controls the underlying intestinal inflammation.
The Crohn’s disease trial will need to show whether the mechanism works across a more heterogeneous and difficult disease. A mixed result between the two indications would not necessarily end development, but it could narrow the candidate’s commercial positioning.
Finally, investors will watch how quickly cAMPfield uses its $180 million and whether the financing carries the company through meaningful mid-stage results. Large launch rounds provide freedom, but parallel global trials can consume capital rapidly.
cAMPfield Therapeutics has assembled experienced investors, an IBD-focused leadership team and a candidate with more clinical history than most newly launched biotechnology assets. The opportunity is credible because patients still need effective oral medicines that combine convenience with manageable long-term safety.
The uncertainty is equally clear. Prifemilast has not yet proved that PDE4B selectivity can deliver deep and durable inflammatory bowel disease remission. The upcoming trials must convert a pharmacological advantage into a clinical one, while competing against a treatment market that has advanced considerably since earlier PDE4 studies were conducted.
